Vertex Pharmaceuticals (VRTX) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Vertex Pharmaceuticals (NASDAQ: VRTX):

• 10/17/2026 – Vertex Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/16/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 10/8/2026 – Vertex Pharmaceuticals had its price target raised by Royal Bank Of Canada from $570.00 to $576.00. They now have an “outperform” rating on the stock.
• 10/2/2026 – Vertex Pharmaceuticals was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 9/28/2026 – Vertex Pharmaceuticals had its price target raised by UBS Group AG from $585.00 to $615.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Vertex Pharmaceuticals had its price target raised by Jefferies Financial Group Inc. from $633.00 to $640.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Vertex Pharmaceuticals had its price target raised by TD Cowen from $525.00 to $550.00. They now have a “buy” rating on the stock.
• 9/21/2026 – Vertex Pharmaceuticals is now covered by Leerink Partners. They set an “outperform” rating and a $594.00 price target on the stock.
• 9/11/2026 – Vertex Pharmaceuticals had its “overweight” rating reaffirmed by JPMorgan Chase & Co.. They now have a $560.00 price target on the stock, up from $515.00.
• 9/10/2026 – Vertex Pharmaceuticals was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 9/2/2026 – Vertex Pharmaceuticals had its price target raised by Evercore Inc from $535.00 to $600.00. They now have an “outperform” rating on the stock.
• 9/1/2026 – Vertex Pharmaceuticals is now covered by Morgan Stanley. They set an “overweight” rating and a $665.00 price target on the stock.
• 9/1/2026 – Vertex Pharmaceuticals was given a new $653.00 price target by The Goldman Sachs Group, Inc.. They now have a “buy” rating on the stock.
• 8/25/2026 – Vertex Pharmaceuticals was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.